Earnings · URGN
URGN

URGN Earnings Preview

UroGen Pharma Ltd. · Healthcare · $1B

14d until earnings

URGN Earnings

Tuesday, May 12 2026
EPS Estimate
$-0.49
$-0.62 – $-0.11
Revenue Estimate
$45M
Current Price
$24.11

Our Position

bullish · high

Zasturi ramp accelerates with permanent J code live

est. revisions rising (+15.8pp / 30d)

The refinancing halves UroGen's cost of capital and eliminates the 2027 maturity wall — the company now has runway to 2030 with no structural excuses. Zasturi's commercial story shifts from reimbursement risk to pure execution: the J code is active, cash is extended, and the market either adopts the product or it doesn't. Q1 2026 earnings will be the acid test of whether reimbursement clarity translates to adoption velocity.

Watch: Q1 2026 earnings (May) will show Zasturi's first full quarter post-J-code activation. Meaningful acceleration from the $15.8M Q4 baseline validates the reimbursement unlock thesis and sets up a multi-quarter narrative; flat or declining revenue would signal market adoption remains challenged despite regulatory clarity.

Data Signal Summary

2 bullish
2 bearish
Estimates up +4% Insider selling cluster Put/call 0.2 (bullish skew) Price downtrend

Key Context

Insider Activity
selling
Price Trend
downtrend
From 52w High
-7.5%
Est. Revisions (30d)
+3.7% 1up/6dn
Analyst Target (mean)
$34 $17–$40 +41%
Options P/C Ratio
0.24
Est. Dispersion
106% 8 analysts
Insider Cluster
strong sell
Fund Convergence
strong Citadel, Renaissance, D.E. Shaw

Recent Activity

insider trades 31 transactions
Sell · SCHOENBERG MARK (Officer) ·7,373 shares ·$145,174
Sell · SMITH JASON DREW (General Counsel) ·7,479 shares ·$147,262
Other · SCHOENBERG MARK (Officer) ·13,333 shares
Other · SMITH JASON DREW (General Counsel) ·15,500 shares
Other · BUTITTA CYNTHIA M (Director) ·2,000 shares
26 more
Other · ROBINSON JAMES A JR. ·2,000 shr
Other · HOLDEN STUART M.D. ·2,000 shr
Other · WEN LEANA ·2,000 shr
Other · WILDMAN DANIEL GEORGE ·2,000 shr
Sell · SCHOENBERG MARK ·10,000 shr ·$250,000
Sell · DEGNAN CHRISTOPHER ·2,203 shr ·$37,121
Other · DEGNAN CHRISTOPHER ·4,483 shr
Sell · SCHOENBERG MARK ·871 shr ·$16,645
Sell · SMITH JASON DREW ·1,520 shr ·$29,047
Other · SCHOENBERG MARK ·1,667 shr
Other · SMITH JASON DREW ·3,333 shr
Sell · SCHOENBERG MARK ·10,000 shr ·$176,900
Sell · SCHOENBERG MARK ·5,149 shr ·$98,552
Other · SCHOENBERG MARK ·10,000 shr
Sell · SMITH JASON DREW ·7,522 shr ·$143,971
Other · SMITH JASON DREW ·16,500 shr
Sell · SCHOENBERG MARK ·5,162 shr ·$38,044
Sell · SCHOENBERG MARK ·4,551 shr ·$50,698
Other · SCHOENBERG MARK ·8,000 shr
Sell · SMITH JASON DREW ·7,379 shr ·$82,202
Other · SMITH JASON DREW ·14,667 shr
Sell · SCHOENBERG MARK ·859 shr ·$11,236
Other · SCHOENBERG MARK ·1,666 shr
Sell · SMITH JASON DREW ·1,521 shr ·$19,895
Other · KIM DONG ·2,500 shr
Sell · SCHOENBERG MARK ·5,153 shr ·$67,401

Explore more

full analysis → Our calls → Earnings calendar →

Other Upcoming Earnings

V V Earnings today AMZN AMZN Earnings tomorrow META META Earnings tomorrow NBIS NBIS Earnings tomorrow MSFT MSFT Earnings tomorrow
See all upcoming earnings →